About the job
Company Overview:
Compass Pathways plc (Nasdaq: CMPS) is an innovative biotechnology company committed to transforming patient access to evidence-based advancements in mental health treatment. Headquartered in London, UK, with a prominent office in New York City, we specialize in pioneering new therapies aimed at enhancing the lives of individuals facing mental health challenges that remain unaddressed by existing therapies.
We are leading a groundbreaking approach to mental health treatment, emphasizing rapid and lasting responses through our investigational COMP360 synthetic psilocybin therapy, which is poised to be a first-in-class solution. COMP360 has garnered Breakthrough Therapy designation from the US FDA and the Innovative Licensing and Access Pathway (ILAP) designation in the UK, focusing on treatment-resistant depression (TRD) to address significant unmet needs in this domain.
Currently in phase 3 of our TRD studies, we have successfully completed phase 2 trials for both post-traumatic stress disorder (PTSD) and anorexia nervosa and are preparing for further late-stage research in PTSD. Our vision is to create a world where mental health encompasses not just the absence of illness but the ability to flourish.
Position Summary:
The Senior Manager, Reporting & SOX will collaborate closely with the Director of External Reporting (East Coast, US) and the Finance team (hybrid US & UK) to play a crucial role in ongoing SEC Reporting, including external audit reviews, as well as SOX compliance through process design and monitoring. This position will also support the UK Statutory Accounts process on an annual basis.
The primary responsibilities will involve enhancing SEC reporting efforts and leading the design, refinement, and documentation of processes associated with the expanding business operations, particularly as we advance towards commercialization. This role will take the lead on process improvement initiatives, documenting and assessing related controls to meet SOX standards. Presently, the Company adheres to SOX 404(a) and anticipates being under scope for 404(b) by FY27.

